Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,800,304
  • Shares Outstanding, K 702,356
  • Annual Sales, $ 15,281 M
  • Annual Income, $ 4,046 M
  • 60-Month Beta 1.69
  • Price/Sales 4.07
  • Price/Cash Flow 9.97
  • Price/Book 10.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 2.27
  • Number of Estimates 2
  • High Estimate 2.31
  • Low Estimate 2.22
  • Prior Year 1.61
  • Growth Rate Est. (year over year) +40.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.26 +8.33%
on 02/28/19
91.57 -2.69%
on 02/20/19
-1.58 (-1.74%)
since 02/19/19
3-Month
58.59 +52.09%
on 12/26/18
91.57 -2.69%
on 02/20/19
+23.53 (+35.88%)
since 12/19/18
52-Week
58.59 +52.09%
on 12/26/18
95.30 -6.50%
on 08/31/18
+0.58 (+0.66%)
since 03/19/18

Most Recent Stories

More News
SmarTrend Watching for Potential Pullback in Shares of Celgene Corp After 1.07% Gain

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $88.17 to a high of $89.20. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $88.97...

CELG : 89.17 (+1.34%)
After Yesterday's Rally of 1.07% Shares Could Potentially Pullback

Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $88.17 to a high of $89.20. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $88.97...

CELG : 89.17 (+1.34%)
PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

CELG : 89.17 (+1.34%)
AZN : 42.84 (+0.61%)
KMDA : 5.87 (-0.68%)
PHAS : 5.50 (-11.72%)
Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients

The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.

CELG : 89.17 (+1.34%)
AGN : 154.66 (+2.53%)
MNK : 23.16 (+1.98%)
PFE : 42.33 (+1.24%)
Celgene Corp (CELG) Breaks Through Resistance at $88.64

Celgene Corp (NASDAQ:CELG) has opened bullishly above the pivot of $88.19 today and has reached the first level of resistance at $88.64. Should the shares continue to rise, the resistance pivots of $89.41...

CELG : 89.17 (+1.34%)
Are Americans More Confident in 2019? 5 Top Picks

U.S. consumers' net worth took a hit in 2018 owing to a stock market meltdown and tepid housing market conditions.

HLT : 86.46 (+0.29%)
CELG : 89.17 (+1.34%)
XLNX : 126.84 (+1.25%)
ANTM : 310.69 (+0.80%)
PWR : 37.54 (+0.35%)
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene

Bristol-Myers Squibb Company (NYSE: BMY) today filed a new investor presentation with the Securities and Exchange Commission (SEC) in connection with its previously announced definitive merger...

CELG : 89.17 (+1.34%)
CELGZ : 1.22 (+6.09%)
BMY : 49.96 (+0.20%)
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).

CELG : 89.17 (+1.34%)
BDSI : 4.91 (-0.20%)
PFE : 42.33 (+1.24%)
BMY : 49.96 (+0.20%)
Celgene (CELG) Stock Sinks As Market Gains: What You Should Know

Celgene (CELG) closed at $87.91 in the latest trading session, marking a -0.62% move from the prior day.

CELG : 89.17 (+1.34%)
Is Celgene (CELG) Outperforming Other Medical Stocks This Year?

Is (CELG) Outperforming Other Medical Stocks This Year?

CELG : 89.17 (+1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CELG with:

Business Summary

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID,...

See More

Key Turning Points

2nd Resistance Point 89.02
1st Resistance Point 88.50
Last Price 89.17
1st Support Level 87.57
2nd Support Level 87.16

See More

52-Week High 95.30
Last Price 89.17
Fibonacci 61.8% 81.28
Fibonacci 50% 76.94
Fibonacci 38.2% 72.61
52-Week Low 58.59

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar